Expert opinion

/

Updates from ASCO: KEYNOTE-789 and NSCLC

By Dr. Aakash Desai Mayo Clinic   KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC   Key Points: The KEYNOTE-789 trial did not